🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Kevin Fernando Medscape Guidelines in Practice from Medscape GoggleDocs Eimear Darcy Dr. Shashank Joshi Selvaseelan Selvarajah InnovAiT Prof Derek Connolly Cristina Tejera louise brady RN 💙 💚 Always my favourite Hack!

🚦Latest Guidelines in Practice from Medscape Medscape Primary Care #hack is live 🔥Paired #hacks covering the diagnosis & management of #HFrEF & #HFpEF in primary care 💡co-authored with legends Patricia Campbell & Eimear Darcy PDF download link in comments 👇🏾

Lovely to see you too Sarah Birkhoelzer @sarah.theheartdoc ! Great chatting and I look forward to our #CVRM collaborations!

🔥A key message from both #HFrEF & #HFpEF Guidelines in Practice from Medscape Primary Care #hacks 🎯 While awaiting specialist assessment for suspected #HF, consider management of congestion with diuresis (e.g. furosemide 40–80 mg or double existing dose) & initiation of an #SGLT2i 👇🏾 PDF link

With❤️Heart Failure Awareness week❤️in full swing,we hope our new Medscape Primary Care #Hack on the diagnosis& management of #HF in Primary Care helps protect ❤️’s in our communities! Kevin Fernando outlines a pertinent practice changing take home #hack message 👇#SGLT2i

🚨 Tirzepatide: Real-world Rx beyond #T2D? 🔹 10K+ 🇺🇸 adults used tirzepatide without ⚪️#T2D 🔸 77% 👩, avg BMI 35.8 — >50% had ≥2 obesity-related complications 🔹 At 6 months: – 55% adherence – 91% still on ≤10mg – Slow dose ⤴️ vs trials 👉 Underlines gap between trial

📢 TyG-BMI: a new vital sign in #MASLD? 🔹 NHANES study (n=8,753): TyG-BMI ⤴️ = ⤴️ all-cause ☠️ & 💔☠️ 🔸 U-shaped risk curve—both high & low TyG-BMI = ⤴️ risk 🔹 TyG-BMI outperformed HOMA-IR for mortality prediction 🔸 HbA1c mediated most of the effect 👉 For MASLD, insulin

Clinical staging to guide management of metabolic disorders and their sequelae: #EAS What is Systemic Metabolic Disorder? It’s not just #obesity. It’s a multi-organ metabolic disease driven by adiposity, insulin resistance, inflammation & lipotoxicity. #MetabolicHealth

📢 Tirzepatide vs Semaglutide: the heavyweight match lands hard 🔹 72w RCT in obesity (no T2D): – Tirzepatide ⤵️ –20.2% – Semaglutide ⤵️ –13.7% 🔸 Waist ⤵️ –18.4cm vs –13.0cm 🔹 More likely to hit ⩾25% loss: 32% vs 16% 🔸 GI AEs common, but discontinuation <10% 👉 Dual

Join Kevin Fernando and Patrick Holmes for a multi-disciplinary approach to the future of CVRM care. We have a fabulous agenda planned for primary and secondary clinicians that will help you stay on top of the evolving CVRM landscape: cvrmukautumnconference2025.co.uk

Join us in spreading vital awareness this Hypertension Awareness Month! 🌍🎙️ Tune in to my podcast with Prof. Ian Wilkinson President of the British and Irish Hypertension Society Let's equip our patients with knowledge. Share this episode with your patients Find BEATWISE the podcast on all

💡BHIVA rapid guidance on statins for primary prevention of CVD in people living with HIV 🎯Key Clinical Takeaway CV risk calculators underestimate risk in #PLWH; offer atorvastatin 20mg to all #PLWH aged ≥40y irrespective of lipid profile or estimated CV risk